Susanne Arnold, MD
Medical Oncology · Lexington, KYNPI 1114934056
Payments from drug & device makers
Across 325 payments — averaging $15,956 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4.3M
- AbbVie$287K
- AstraZeneca$123K
- Amgen$103K
- Exelixis Inc.$87K
- Eli Lilly$62K
- plus $257K from 13 others
What the payments were for
- Education$99100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 151 | $4,267,596 |
| AbbVie | 25 | $286,976 |
| AstraZeneca | 13 | $122,544 |
| Amgen | 1 | $102,784 |
| Exelixis Inc. | 39 | $86,662 |
| Eli Lilly | 3 | $61,589 |
| GSK | 19 | $37,297 |
| Sagent Pharmaceuticals | 2 | $36,000 |
| F. Hoffmann-la Roche AG | 13 | $34,040 |
| Genmab U.S., Inc. | 5 | $33,756 |
| Incyte Corporation | 27 | $30,373 |
| Astrazeneca UK Limited | 3 | $25,323 |
| Regeneron | 7 | $24,744 |
| Genentech, Inc. | 7 | $12,726 |
| Mirati Therapeutics, Inc. | 5 | $10,600 |
| United Therapeutics Corporation | 2 | $6,731 |
| Beigene USA, Inc. | 1 | $3,000 |
| Tesaro, Inc. | 1 | $2,703 |
| Johnson & Johnson | 1 | $99 |
How this compares
$5,185,543 in reported general payments places this provider in the 95th percentile of 53 medical oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 21 | $309,218 |
| EliquisApixaban | 30 | $24,956 |
| Oxycodone Hcl | 252 | $15,875 |
| Ondansetron Hcl | 98 | $9,810 |
| Fentanyl | 48 | $4,541 |
| Gabapentin | 107 | $3,826 |
| Levothyroxine Sodium | 287 | $2,897 |
| Ondansetron OdtOndansetron | 66 | $1,926 |
| Prochlorperazine Maleate | 109 | $1,411 |
| Dexamethasone | 60 | $1,227 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $1,115 |
| ValacyclovirValacyclovir Hcl | 13 | $959 |
| Ventolin HfaAlbuterol Sulfate | 16 | $924 |
| Megestrol Acetate | 11 | $899 |
| Famotidine | 22 | $509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $122,544 | $309,21821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 medical oncology providers in Kentucky.
Other medical oncology in Lexington
- Zhonglin HaoLexington$3.5M
- Zin MyintLexington$3.4M
- Ralph ZinnerLexington$760K
- Reema PatelLexington$656K
- Lowell AnthonyLexington$520K
- Shawn PetersonLexington$505K
- Peng WangLexington$251K
- Arvinda PadmanabhanLexington$43K
- Ruta AraysLexington$39K
- Robert DipaolaLexington$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.